

GENERIC STEP THERAPY PLANS (GSTP)

DRUG CLASS

BENIGN PROSTATIC HYPERPLASIA (BPH)-1

HPGST SSB – Ref# 605-D: Cardura XL

TGST SSB – Ref# 606-D: Cardura XL

Status: CVS Caremark Criteria

Type: Initial Step Therapy; Post Step Therapy Prior Authorization

INITIAL STEP THERAPY

If the patient has filled a prescription for at least a 30 day supply of a generic Benign Prostatic Hyperplasia (BPH) agent within the past 365 days under a prescription benefit administered by CVS Caremark, then the requested branded drug will be paid under that prescription benefit. If the patient does not meet the step therapy criteria, then the system will reject the claim with the message indicating that prior authorization is needed. The PA criteria for approval would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA

Branded Alpha-1 adrenergic blockers will be covered with post step therapy prior authorization when the following criteria are met:

- Patient has experienced an inadequate treatment response, intolerance, contraindication or potential drug interaction to at least one generic alpha-1 adrenergic blocker drug.

RATIONALE

If the patient has filled a prescription for at least a 30 day supply of a generic Benign Prostatic Hyperplasia (BPH) agent within the past 365 days under a prescription benefit administered by CVS Caremark, then the requested branded drug will be paid under that prescription benefit.

If the patient does not meet the initial step therapy criteria, then prior authorization is required.

If the patient has a documented contraindication to or a potential drug interaction with a generic drug, then the requested brand drug will be covered. If the patient is intolerant to at least one of the generic drugs, then the requested brand drug will be covered. If the patient has tried one of the generic drugs for at least 30 days and had an inadequate treatment response, then the requested brand drug will be covered. If these requirements are met, then the approval duration is 24 months.

REFERENCES

N/A

Written by: UM Development (NB)

Date Written: 01/2011

Revised: 05/2011, 08/2011, 11/2011, 09/2012 (updated formatting and documentation), 10/2012 (removed documentation), 11/2012, 11/2013 (reworded question #2), 11/2014, 04/2015 (specified Alpha-1 adrenergic blocker in the questions), 11/2015, 11/2016 (no changes), (SF) 11/2017 (no changes), 10/2018 (no changes), 01/2019 (remove Rapaflo)

GSTP BPH-Alpha-1 Adrenergic Blockers

© 2018 Caremark. All rights reserved. This document contains confidential, privileged and proprietary information of CVS/caremark. It cannot be reproduced, distributed or printed without written permission from CVS/caremark. Clinical criteria may change at any time based on at-risk generic launches, new drug approvals, formulary changes and other market and regulatory events. Updates to the clinical criteria and GSTP may be made quarterly. This page contains prescription brand name drugs that are registered or trademarks of pharmaceutical manufacturers that are not affiliated with CVS/caremark Inc.

Reviewed: Medical Affairs (KP) 01/2011, 08/2011, 11/2011; (DC) 09/2012, 11/2012, (LS) 11/2013, (DC) 11/2014, (KU) 04/2015
External Review: 03/2011, 03/2012, 02/2013, 02/2014, 02/2015, 02/2016, 02/2017, 02/2018, 02/2019

GSTP BPH-Alpha-1 Adrenergic Blockers

© 2018 Caremark. All rights reserved. This document contains confidential, privileged and proprietary information of CVS/caremark. It cannot be reproduced, distributed or printed without written permission from CVS/caremark. Clinical criteria may change at any time based on at-risk generic launches, new drug approvals, formulary changes and other market and regulatory events. Updates to the clinical criteria and GSTP may be made quarterly. This page contains prescription brand name drugs that are registered or trademarks of pharmaceutical manufacturers that are not affiliated with CVS/caremark Inc.